| Literature DB >> 25691931 |
Najmeh Ranji1, Majid Sadeghizadeh2, Morteza Karimipoor3, Mohammad Ali Shokrgozar4, Reza Ebrahimzadeh-Vesal5.
Abstract
OBJECTIVES: Study of non-coding RNAs is considerable to elucidate principal biological questions or design new therapeutic strategies. miRNAs are a group of non-coding RNAs that their functions in PI3K/AKT signaling and apoptosis pathways after T cell activation is not entirely clear. Herein, miRNAs expression and their putative targets in the mentioned pathways were studied in the activated CD4(+)T cells.Entities:
Keywords: AKT3; IL-2 induction; In silico analysis; miRNAs
Year: 2014 PMID: 25691931 PMCID: PMC4328098
Source DB: PubMed Journal: Iran J Basic Med Sci ISSN: 2008-3866 Impact factor: 2.699
Figure 1.Proliferation analysis by BrdU incorporation (ELISA) assay. Optical density (OD) of treated and un-treated cells by anti-CD2, CD3, CD28 and/or IL-2 revealed the most proliferative rate in activated cells after IL-2 induction during 3 days. Significant difference (P < 0.0001 by one-way ANOVA) in the proliferation rate between IL-2 induced cells and activated ones with un-treated cells was statically measured. Representative data from at least three experiments are shown. The results are presented as mean ± SD
Figure 2.CD45RA+CD4+T cells count after activation with anti-CD2,CD3,CD28 microbeads alone (A) and along with IL-2(B). Flow cytometry analysis showed decrease of CD4+CD45RA+T cells in IL-2 induced cells compared to IL-2 depleted cells
Figure 3.IL-2 production was measured in the supernatants of cultured cells during 3 days after IL-2 induction by ELISA. Cytokine production was significantly higher in the cultures from IL-2 treated cells compared to activated or un-treated cells (P<0.0001 by t-test). It is noticeable that cytokine secretion by un-treated CD4+CD45RA+ T cells and activated cells (by microbeads) was not detectable. Representative data from at least three experiments are shown. The results are represented as mean ±SD
Potential targets of the most modulated miRNAs in two cell groups predicted by algorithms such as TargetScan, miRanda, Diana microT and miRWalk
| Upregulated miRNAs in IL-2 depleted cells | Target genes | Upregulated miRNAs in IL-2 induced cells | Target genes |
| hsa-miR-342-3p | AKT2, BCL2L1, CREB1, GSK3, BCL2L11(Bim), CYCS | hsa-miR-634 | AKT2, CYCS, BCL2L1, PUMA, BCL2L11 |
| hsa-miR-942 | AKT1, AKT3, APAF1, FAS , GSK3, CYCS, BCL2,FASL | hsa-miR-192* | PIM1,CYCS |
| hsa-miR-92a-2* | AKT1, AKT2, AKT3, APAF1, CYCS | hsa-miR-595 | APAF1,CYCS, BCL2L1, GSK3, BCL2L11, BCL2 |
| hsa-miR-328 | AKT1, AKT3, PIM1, APAF1, CYCS, AKT2, BCL2L1 (BCL-XL), GSK3, NOXA, PUMA, BCL2L11 | hsa-miR-580 | PIM1, CYCS, CREB1, NFKB2, BCL2L11 |
| hsa-miR-766 | MDM2, PIM1,APAF1, CYCS, AKT2, BCL2L1, DR5, FAS, GSK3, PUMA, BCL2L11 | hsa-miR-941 | AKT1, GSK3 |
| hsa-miR-938 | APAF1, BCL2L1, GSK3, CDKN1A (p21), BCL2L11 | hsa-miR-586 | AKT1, APAF1, CREB1,BCL2L11, CYCS, BCL2,FASL |
| hsa-miR-106a | AKT3, MDM2, APAF1, CYCS, BCL2L1, CREB1, DR5, GSK3, CDKN1A, BCL2L11, BCL2, FASL | hsa-miR-558 | AKT2, AKT3, PIM1, APAF1, BCL2L1,CREB1, GSK3, CDKN1A, BCL2L11, BCL2 |
| hsa-miR-501-3p | AKT1,AKT3, APAF1, AKT2, NOXA, FASL | hsa-miR-487a | AKT2, CYCS, DR5,FAS , NOXA, AKT3,IL-2,FASL |
| hsa-miR-30d* | AKT2, AKT3, PIM1, APAF1, CREB, CYCS, FASL | hsa-miR-520f | AKT1, AKT2, AKT3, MDM2, CREB1, DR5, GSK3, CDKN1A, BCL2L11 ,FASL |
| hsa-miR-590-5p | APAF1, CREB1, DR5, BCL2 ,FASL | hsa-miR-181c* | AKT2, AKT3, PIM1,CREB1 |
| hsa-miR-20a | MDM2, CREB1, DR5, FAS, GSK3, NOXA, CDKN1A, BCL2L11, AKT3, CYCS, FASL | hsa-miR-548c-5p | AKT3, NFKB1,MDM2, APAF1, BAX, DR5,GSK3,NOXA,BCL2L11 |
| hsa-miR-192 | PIM1, CYCS, CREB1, GSK3, BCL2L11,FASL | hsa-miR-886-3p | AKT2, DR5,GSK3,PUMA |
| hsa-miR-16-2* | AKT3, CYCS, FASL | hsa-miR-665 | AKT1, AKT2, AKT3, MDM2, DR5 ,GSK3, CDKN1A, PUMA, BCL2L11 |
| hsa-miR-425* | PIM1, CYCS | hsa-miR-512-3p | AKT1 |
| hsa-miR-338-5p | AKT3, NFKB1, APAF1, CREB1,DR5, GSK3 , BCL2L11, BCL2,IL-2 ,FASL | ||
| hsa-miR-23a | AKT2, APAF1, CYCS, DR5, FAS, NOXA, BCL2L11, BCL2 | ||
| hsa-miR-222 | AKT2, MDM2, APAF1, CYCS, PUMA, BCL2L11, BCL2, FASL | ||
| hsa-miR-20a* | AKT2, AKT3, BCL2L11, CYCS, FASL | ||
| hsa-miR-93 | AKT3, APAF1, CYCS, CREB1, FAS, GSK3, NOXA, CDKN1A, BCL2L11, BCL2, FASL | ||
| hsa-miR-155 | APAF1, CREB1,DR5, BCL2 | ||
| hsa-miR-218 | AKT3, CYCS, CREB1,DR5 , GSK3 | ||
| hsa-miR-374a | AKT1, AKT3, MDM2, APAF1, CYCS, FAS, GSK3, NOXA | ||
| hsa-miR-532-5p | AKT3, MDM2, CYCS, DR5 | ||
| hsa-miR-130b | AKT2, APAF1, CREB1, DR5, GSK3, CDKN1A, PUMA, BCL2L11 | ||
| hsa-miR-215 | PIM1,CREB1, GSK3, BCL2L11 | ||
| hsa-miR-888 | AKT2, AKT3, APAF1, CREB1,FAS, NOXA, BCL2L11 | ||
| hsa-miR-330-3p | AKT2, AKT3, APAF1, DR5,FAS , GSK3,NFKB1, BCL2L11 | ||
| hsa-miR-185* | AKT1, AKT2, PIM1, CDKN1A | ||
| hsa-miR-371-3p | AKT2, GSK3, CDKN1A | ||
| hsa-miR-32 | DR5, GSK3, BCL2L11, FASL, FASL | ||
| hsa-miR-105 | AKT1, AKT2, AKT3, CREB1, GSK3, CDKN1A, BCL2L11 | ||
| hsa-miR-195 | AKT2, AKT3, PIM1, DR5, FAS, CDKN1A, BCL2L11, BCL2 | ||
| hsa-miR-323-5p | FAS , GSK3, CDKN1A, PUMA | ||
| hsa-miR-513a-3p | MDM2, PIM1,CREB1, FAS, GSK3 | ||
| hsa-miR-520a-3p | AKT1, AKT2, AKT3, CREB1,DR5,GSK3, CDKN1A, BCL2L11, BCL2 , FASL | ||
| hsa-miR-130b* | PIM1,CREB1, FASL | ||
| hsa-miR-548h | AKT3, MDM2, APAF1, DR5, GSK3, NFKB1, NOXA | ||
| hsa-miR-561 | AKT2, AKT3, CREB1, DR5, FAS, GSK3, NOXA, CDKN1A, BCL2L11 | ||
| hsa-miR-589* | AKT3, PIM1, FAS, GSK3 | ||
| hsa-miR-34b* | AKT3, PIM1,CREB1 | ||
| hsa-miR-424* | AKT1, AKT3, PIM1 | ||
| hsa-miR-517c | FASL | ||
| hsa-miR-607 | AKT2, AKT3, PIM1, CREB1, BCL2L1,DR5,FAS, GSK3,NOXA | ||
| hsa-miR-378 | APAF1, BCL2L1, GSK3 | ||
| hsa-miR-1236 | AKT3, PIM1, APAF1, CREB1, GSK3,PUMA, DR5 | ||
| hsa-miR-486-5p | PIM1, BCL2L1, GSK3 | ||
| hsa-miR-148b | AKT3, CREB1, CDKN1A, PUMA, PUMA, BCL2L11, | ||
| hsa-miR-181a | AKT2, AKT3,CREB1,FAS, GSK3, NOXA, BCL2L11, BCL2, IL-2, FASL | ||
| hsa-miR-211 | AKT2,APAF1, CREB1, BCL2L1, GSK3 | ||
| hsa-miR-99b | GSK3 | ||
| hsa-miR-24 | AKT2, AKT3, MDM2, Pim1, APAF1, CREB1, GSK3, PUMA,BCL2L11, BCL2, FASL | ||
| hsa-miR-200c | AKT2, AKT3,CREB1,NOXA | ||
| hsa-miR-548b-3p | AKT1, MDM2, CREB1, FASL | ||
| hsa-miR-150 | AKT2, AKT3, PIM1, APAF1, Bax,CREB1, PUMA | ||
| hsa-let-7i* | AKT1, AKT2, PIM1, FASL | ||
| hsa-miR-23b | APAF1, AKT2,DR5,FAS, GSK3, NOXA, BCL2 | ||
| hsa-miR-21 | DR5, APAF1, BCL2, FASL | ||
| hsa-miR-1260 | AKT2, DR5, GSK3, PUMA | ||
| hsa-miR-31 | Pim1, GSK3 | ||
| hsa-miR-92a | MDM2, CREB1, DR5, GSK3, BCL2L11, FASL | ||
| hsa-miR-200b* | DR5, AKT2, AKT3 | ||
| hsa-miR-744* | AKT1, AKT2, AKT3 | ||
| hsa-miR-324-5p | GSK3, PUMA | ||
| hsa-miR-151-5p | AKT2, MDM2, GSK3 | ||
| hsa-miR-25 | AKT2, MDM2, APAF1, DR5,FAS,GSK3, BCL2L11, FASL | ||
| hsa-miR-940 | AKT2, MDM2, APAF1, Bax,DR5,GSK3,CDKN1A, PUMA | ||
| hsa-miR-197 | AKT2, NOXA, BCL2 | ||
| hsa-miR-501-5p | AKT3, NFKB2 | ||
| hsa-miR-181b | AKT2,AKT3, DR5, FAS,GSK3,NOXA, BCL2L11 BCL2, IL-2, FASL |
Figure 4.Quantitative expression of AKT1 and AKT3 in IL-2 induced cells compared to IL-2 depleted ones. Relative expression of AKT1 and AKT3 was normalized to GAPDH. Representative data from at least three experiments are shown. Asterisks indicate significant differences the groups (* P <0.05). The results are represented as mean ±SD